These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20218998)

  • 1. Informing policy for the Australian context - Costs, outcomes and cost savings of prenatal carrier screening for cystic fibrosis.
    Maxwell S; Brameld K; Youngs L; Geelhoed E; O'Leary P
    Aust N Z J Obstet Gynaecol; 2010 Feb; 50(1):51-9. PubMed ID: 20218998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of prenatal carrier screening for cystic fibrosis.
    Lieu TA; Watson SE; Washington AE
    Obstet Gynecol; 1994 Dec; 84(6):903-12. PubMed ID: 7970468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of carrier screening for cystic fibrosis in Australia.
    Norman R; van Gool K; Hall J; Delatycki M; Massie J
    J Cyst Fibros; 2012 Jul; 11(4):281-7. PubMed ID: 22425241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prenatal screening for cystic fibrosis: an economic analysis.
    Nielsen R; Gyrd-Hansen D
    Health Econ; 2002 Jun; 11(4):285-99. PubMed ID: 12007162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community-wide screening for cystic fibrosis carriers could replace newborn screening for the diagnosis of cystic fibrosis.
    Massie J; Forbes R; Dusart D; Bankier A; Delatycki MB
    J Paediatr Child Health; 2007 Nov; 43(11):721-3. PubMed ID: 17924936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preconception screening of parents and carrier state of cystic fibrosis in the Netherlands: expenses and savings].
    Verheij JB; Hilderink HB; Verzijl JG; Wildhagen MF; Habbema JD; ten Kate LP
    Ned Tijdschr Geneeskd; 1998 Mar; 142(13):706-10. PubMed ID: 9623144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-benefit analysis of preimplantation genetic diagnosis for carrier couples of cystic fibrosis.
    Davis LB; Champion SJ; Fair SO; Baker VL; Garber AM
    Fertil Steril; 2010 Apr; 93(6):1793-804. PubMed ID: 19439290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India.
    Kumar M; Birch S; Maturana A; Gafni A
    Health Policy; 2006 Jul; 77(2):233-43. PubMed ID: 16126300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the costs of diagnosing cystic fibrosis with a newborn screening program.
    Lee DS; Rosenberg MA; Peterson A; Makholm L; Hoffman G; Laessig RH; Farrell PM
    J Pediatr; 2003 Jun; 142(6):617-23. PubMed ID: 12838188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carrier screening for cystic fibrosis: costs and clinical outcomes.
    Asch DA; Hershey JC; Dekay ML; Pauly MV; Patton JP; Jedrziewski MK; Frei F; Giardine R; Kant JA; Mennuti MT
    Med Decis Making; 1998; 18(2):202-12. PubMed ID: 9566453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of prenatal carrier screening for fragile X syndrome.
    Vintzileos AM; Ananth CV; Fisher AJ; Smulian JC; Day-Salvatore D; Beazoglou T; Knuppel RA
    J Matern Fetal Med; 1999; 8(4):168-72. PubMed ID: 10406300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic fibrosis screening at the Greenville Hospital System.
    Dacus J; Mabie B; Gailey T; Rogers C; Likes C; Metcalf L
    J S C Med Assoc; 2006 Feb; 102(1):14-6. PubMed ID: 16704181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is cystic fibrosis carrier screening cost effective?
    Wei S; Quigg MH; Monaghan KG
    Community Genet; 2007; 10(2):103-9. PubMed ID: 17380060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-based carrier screening for cystic fibrosis in Victoria: the first three years experience.
    Massie J; Petrou V; Forbes R; Curnow L; Ioannou L; Dusart D; Bankier A; Delatycki M
    Aust N Z J Obstet Gynaecol; 2009 Oct; 49(5):484-9. PubMed ID: 19780730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When does mass screening for open neural tube defects in low-risk pregnancies result in cost savings?
    Tosi LL; Detsky AS; Roye DP; Morden ML
    CMAJ; 1987 Feb; 136(3):255-65. PubMed ID: 2433011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The introduction of cystic fibrosis carrier screening into clinical practice: policy considerations.
    Wilfond BS; Fost N
    Milbank Q; 1992; 70(4):629-59. PubMed ID: 1435628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reproductive decision making of aunts and uncles of a child with cystic fibrosis: genetic risk perception and attitudes toward carrier identification and prenatal diagnosis.
    Denayer L; Evers-Kiebooms G; De Boeck K; Van den Berghe H
    Am J Med Genet; 1992 Sep; 44(1):104-11. PubMed ID: 1519639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
    Anderson R; Haas M; Shanahan M
    Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis.
    van den Akker-van Marle ME; Dankert HM; Verkerk PH; Dankert-Roelse JE
    Pediatrics; 2006 Sep; 118(3):896-905. PubMed ID: 16950979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic fibrosis carrier screening: knowledge and attitudes of prenatal care providers.
    Rowley PT; Loader S; Levenkron JC; Phelps CE
    Am J Prev Med; 1993; 9(5):261-6. PubMed ID: 8257614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.